强化抗结核方案治疗耐药结核性脑膜炎的临床结局
该研究纳入817例结核性脑膜炎患者中的322例已知耐药谱者,比较标准方案与强化方案(高剂量利福平+左氧氟沙星)的9个月生存。多变量分析显示MDR是死亡的独立预测因素(HR 5.91),INH-R与不良复合结局相关,强化治疗显著改善INH-R患者生存(HR 0.34)。
要点
- MDR是结核性脑膜炎死亡的独立预测因素(HR 5.91)。
- INH-R与新增神经系统事件或死亡复合结局显著相关(HR 1.58)。
- 强化治疗显著改善INH-R结核性脑膜炎患者生存(HR 0.34)。
核心结论
- 早期强化治疗改善INH-R结核性脑膜炎患者生存。
- 针对耐药结核性脑膜炎的靶向方案有待进一步探索。
研究设计与样本
- 对一项随机对照试验入组的结核性脑膜炎患者进行亚组分析。
- 共817例随机患者中322例有已知耐药谱。
- 比较标准9个月方案(利福平10 mg/kg/天)与强化方案(前8周利福平15 mg/kg/天+左氧氟沙星20 mg/kg/天)。
- 主要终点为9个月生存。
主要发现
- INH-R 86例(26.7%),MDR 15例(4.7%),利福平单耐药1例(0.3%),INH-S+RIF-S 220例(68.3%)。
- INH-R与新增神经系统事件或死亡的复合结局显著相关(HR 1.58 [95%CI 1.11-2.23])。
临床怎么用
- 对INH-R结核性脑膜炎患者,早期强化抗结核治疗可能改善生存。
- MDR结核性脑膜炎死亡风险高,需关注并探索靶向方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug-resistant tuberculous meningitis (TBM) is difficult to diagnose and treat. Mortality is high and optimal treatment is unknown. We compared clinical outcomes of drug-resistant and -susceptible TBM treated with either standard or intensified antituberculosis treatment. METHODS: We analyzed the influence of Mycobacterium tuberculosis drug resistance on the outcomes of patients with TBM enrolled into a randomized controlled trial comparing a standard, 9-month antituberculosis regimen (containing rifampicin 10 mg/kg/day) with an intensified regimen with higher-dose rifampicin (15 mg/kg/day) and levofloxacin (20 mg/kg/day) for the first 8 weeks. The primary endpoint of the trial was 9-month survival. In this subgroup analysis, resistance categories were predefined as multidrug resistant (MDR), isoniazid resistant, rifampicin susceptible (INH-R), and susceptible to rifampicin and isoniazid (INH-S + RIF-S). Outcome by resistance categories and response to intensified treatment were compared and estimated by Cox regression. RESULTS: Of 817 randomized patients, 322 had a known drug resistance profile. INH-R was found in 86 (26.7%) patients, MDR in 15 (4.7%) patients, rifampicin monoresistance in 1 patient (0.3%), and INH-S + RIF-S in 220 (68.3%) patients. Multivariable regression showed that MDR (hazard ratio [HR], 5.91 [95% confidence interval {CI}, 3.00-11.6]), P < .001), was an independent predictor of death. INH-R had a significant association with the combined outcome of new neurological events or death (HR, 1.58 [95% CI, 1.11-2.23]). Adjusted Cox regression, corrected for treatment adjustments, showed that intensified treatment was significantly associated with improved survival (HR, 0.34 [95% CI, .15-.76], P = .01) in INH-R TBM. CONCLUSIONS: Early intensified treatment improved survival in patients with INH-R TBM. Targeted regimens for drug-resistant TBM should be further explored. CLINICAL TRIALS REGISTRATION: ISRCTN61649292.
引用
- Heemskerk AD, Nguyen MTH, Dang HTM, et al. Clinical Outcomes of Patients With Drug-Resistant Tuberculous Meningitis Treated With an Intensified Antituberculosis Regimen. Clin Infect Dis. 2017. PMID: 28472255. doi:10.1093/cid/cix230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。